Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2012

View Archived Issues

BMS and Duke Translational Medicine Institute broaden their collaboration

Researchers identify biomarker for ulcer-type interstitial cystitis

Potassium channel blocker has antiobesity effects in animal models

Collaborating Australian universities design new candidate schizophrenia therapies

New marker and potential therapeutic target identified for castration-resistant prostate cancer

AVI BioPharma clear to proceed with studies of AVI-6003 component

Merck & Co. designs new products with potential to treat hepatitis C

Amgen divulges novel beta-secretase 1 inhibitors

Novel ALK inhibitors created with anticancer potential

Merck KGaA reports new P70S6K inhibitors

Novel protease-activated PAR2 receptor ligands developed in Australia

New protein kinase inhibitors identified at Nerviano Medical Sciences

Dainippon Sumitomo Pharma reaches agreement on acquisition

OncoTherapy Science updates on cancer peptide vaccine pipeline

BCI-838 enters new phase I trial

Shire and arGEN-X to develop therapeutic antibodies for rare diseases

Creabilis begins phase IIb CT-327 study

Biotie completes PET imaging study of serotonin 5-HT6 receptor antagonist

Essentialis reports results from phase IIb trial of DCCR

Baxter International begins study of stem cell therapy for chronic myocardial ischemia

FDA accepts Tau Therapeutics' IND for repositioned drug

Johns Hopkins and ImmunoCellular Therapeutics enter licensing agreement for cancer antigen

Polaris begins dosing in study of cancer therapy in pediatric patients

Global rights to biocrea phosphodiesterase program transferred

FDA grants orphan drug status to treatment for lysosomal storage disorder

Avanir and Concert Pharmaceuticals to develop deuterium-modified dextromethorphan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...